Clinical trials: Blindness
Visual Fields Hemianopsia, Hemianopsia, Homonymous
Visual Perceptual Learning Based Digital Therapeutics for Visual Field Defect After Stroke
This study evaluates the efficacy of visual perceptual learning for the treatment of visual field defect caused by brain disease. Half of participants will receive visual perceptual training using the VIVID Brain.
- Trial name
- NCT05525949
- Testing
- VIVID Brain, No-treatment Control
- Where
- 12 sites in South Korea
- Volunteers
- 93 people
- Sponsor
- Nunaps Inc
Viral Keratitis, Blindness Eye
Safety and Efficacy of CRISPR/Cas9 mRNA Instantaneous Gene Editing Therapy to Treat Refractory Viral Keratitis
The purpose of this study is to evaluate the safety, tolerability and efficacy of a single escalating doses of BD111 CRISPR/Cas9 mRNA Instantaneous Gene Editing Therapy administered via corneal injection in participants with…
- Conditions
- Viral Keratitis, Blindness Eye, Herpes Simplex Virus Infection, Cornea
- Trial name
- NCT04560790
- Testing
- BD111 Adult single group Dose
- Where
- China
- Volunteers
- 3 people
- Sponsor
- Shanghai BDgene Co., Ltd.
Spinal Cord Injury
A Safety Study for Cethrin (BA-210) in the Treatment of Acute Thoracic and Cervical Spinal Cord Injuries
This trial is a multi-center, open-label, dose-escalation study designed to evaluate the safety, tolerability and pharmacokinetics of Cethrin in two types of spinal cord injury patients: those with a complete cervical injury or a…
- Trial name
- NCT00500812
- Testing
- Cethrin
- Where
- 8 sites in United States, Canada
- Volunteers
- 48 people
- Sponsor
- Vertex Pharmaceuticals Incorporated
Retinitis Pigmentosa, Usher Syndrome Type 2
Retinal Imaging in CNTF -Releasing Encapsulated Cell Implant Treated Patients for Early-stage Retinitis Pigmentosa
This clinical trial is a single-site, 30 patient study for participants who have early stage retinitis pigmentosa, or Usher syndrome (type 2 or 3). Funding Source - FDA OOPD and Foundation Fighting Blindness.
- Conditions
- Retinitis Pigmentosa, Usher Syndrome Type 2, Usher Syndrome Type 3
- Trial name
- NCT01530659
- Testing
- NT-501
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Neurotech Pharmaceuticals